Florin Court Capital LLP Has $508,000 Position in iShares Biotechnology ETF (NASDAQ:IBB)

Florin Court Capital LLP cut its position in shares of iShares Biotechnology ETF (NASDAQ:IBB) by 76.0% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 3,700 shares of the financial services provider’s stock after selling 11,700 shares during the quarter. iShares Biotechnology ETF accounts for 0.7% of Florin Court Capital LLP’s portfolio, making the stock its 25th biggest holding. Florin Court Capital LLP’s holdings in iShares Biotechnology ETF were worth $508,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in IBB. BNP Paribas Financial Markets lifted its holdings in shares of iShares Biotechnology ETF by 25.7% during the first quarter. BNP Paribas Financial Markets now owns 2,055,373 shares of the financial services provider’s stock valued at $282,038,000 after acquiring an additional 420,053 shares during the period. Global Assets Advisory LLC bought a new stake in iShares Biotechnology ETF in the first quarter valued at about $66,059,000. Raymond James Financial Services Advisors Inc. boosted its holdings in iShares Biotechnology ETF by 24.6% during the second quarter. Raymond James Financial Services Advisors Inc. now owns 217,047 shares of the financial services provider’s stock worth $29,792,000 after buying an additional 42,822 shares during the last quarter. Commonwealth Equity Services LLC grew its position in shares of iShares Biotechnology ETF by 5.3% during the 1st quarter. Commonwealth Equity Services LLC now owns 198,709 shares of the financial services provider’s stock worth $27,267,000 after buying an additional 10,033 shares during the period. Finally, Raymond James & Associates increased its stake in shares of iShares Biotechnology ETF by 4.4% in the 2nd quarter. Raymond James & Associates now owns 189,766 shares of the financial services provider’s stock valued at $26,047,000 after acquiring an additional 7,931 shares during the last quarter. 62.45% of the stock is owned by institutional investors and hedge funds.

iShares Biotechnology ETF Price Performance

iShares Biotechnology ETF stock opened at $144.79 on Friday. The company’s 50 day simple moving average is $144.01 and its 200 day simple moving average is $137.94. iShares Biotechnology ETF has a fifty-two week low of $111.83 and a fifty-two week high of $150.17.

iShares Biotechnology ETF Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.